Results 11 to 20 of about 2,674,610 (386)
Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis [PDF]
Open Veterinary Journal, 2022 Background: Hyperinsulinemia associated with pituitary pars intermedia dysfunction (PPID) and/or equine metabolic syndrome (EMS) is well documented to put horses at high risk of laminitis.
Eleanor M. Kellon, Kathleen M. Gustafson
doaj +1 more source
STAR Protocols, 2023 Summary: Human subcutaneous adipocytes are an attractive therapeutic target in regulating overall physiological homeostasis. However, the differentiation of primary human adipose-derived models remains challenging.
Ajit Regmi, William Roell
doaj +1 more source
Molecular and Cellular Bases of Lipodystrophy Syndromes
Frontiers in Endocrinology, 2022 Lipodystrophy syndromes are rare diseases originating from a generalized or partial loss of adipose tissue. Adipose tissue dysfunction results from heterogeneous genetic or acquired causes, but leads to similar metabolic complications with insulin ...
Jamila Zammouri +20 more
doaj +1 more source
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors
Open Veterinary Journal, 2023 Background: Sodium-Glucose CoTransporter-2 [SGLT2] inhibitors, the -flozin group of drugs, which block glucose reuptake in the renal proximal tubule, are being increasingly used off-label to treat horses with refractory hyperinsulinemia. After two years
Eleanor M. Kellon, Kathleen M. Gustafson
doaj +1 more source
Frontiers in Endocrinology, 2022 Heterozygous loss-of-function variants of the glucokinase (GCK) gene are responsible for a subtype of maturity-onset diabetes of the young (MODY). GCK-MODY is characterized by a mild hyperglycemia, mainly due to a higher blood glucose threshold for ...
José Timsit +14 more
doaj +1 more source
Possible dysmetabolic hyperferritinemia in hyperinsulinemic horses [PDF]
Open Veterinary Journal, 2019 Background: Hyperinsulinemia associated with equine metabolic syndrome (EMS) and pituitary pars intermedia dysfunction (PPID) is a risk factor for laminitis.
Eleanor M. Kellon, Kathleen M. Gustafson
doaj +1 more source
Comparative analysis of fetomaternal outcome in women with gestational diabetes mellitus managed on different modalities [PDF]
New Indian Journal of OBGYN, 2022 Objectives: To compare fetomaternal outcome in women of gestational diabetes mellitus (GDM) managed on different modalities. Methods: A retrospective observational study was conducted in department of obstetrics and gynaecology at Vardhman Mahavir ...
Sumedha Gupta +4 more
doaj +1 more source
Hyperosmolar hyperglycemic state as the first manifestation of type 1 diabetes mellitus in an adolescent male: a case report [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2022 A hyperosmolar hyperglycemic state (HHS) is a life-threatening complication rarely seen in children and adolescents with type 1 diabetes mellitus (T1DM).
Sang Hoon Chun +2 more
doaj +1 more source
New Insulins, Biosimilars, and Insulin Therapy [PDF]
Diabetes Technology & Therapeutics, 2016 Exogenous insulin has greatly changed the outlook for patients with diabetes ever since its discovery and isolation. Yet, serious complications can result as patients experience both hyperglycemic and hypoglycemic states, even when they strictly follow an insulin regimen. Several chemically or genetically modified insulins have been developed that tune
Lutz Heinemann +2 more
openaire +13 more sources
Orphanet Journal of Rare Diseases, 2022 Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole National
H. Mosbah +36 more
doaj +1 more source